Simvastatin profoundly impairs energy metabolism in primary human muscle cells
- PMID: 33295884
- PMCID: PMC7780958
- DOI: 10.1530/EC-20-0444
Simvastatin profoundly impairs energy metabolism in primary human muscle cells
Abstract
Objectives: Simvastatin use is associated with muscular side effects, and increased risk for type 2 diabetes (T2D). In clinical use, simvastatin is administered in inactive lipophilic lactone-form, which is then converted to active acid-form in the body. Here, we have investigated if lactone- and acid-form simvastatin differentially affect glucose metabolism and mitochondrial respiration in primary human skeletal muscle cells.
Methods: Muscle cells were exposed separately to lactone- and acid-form simvastatin for 48 h. After pre-exposure, glucose uptake and glycogen synthesis were measured using radioactive tracers; insulin signalling was detected with Western blotting; and glycolysis, mitochondrial oxygen consumption and ATP production were measured with Seahorse XFe96 analyzer.
Results: Lactone-form simvastatin increased glucose uptake and glycogen synthesis, whereas acid-form simvastatin did not affect glucose uptake and decreased glycogen synthesis. Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3β (GSK3β) was upregulated with lactone-, but not with acid-form simvastatin. Exposure to both forms of simvastatin led to a decrease in glycolysis and glycolytic capacity, as well as to a decrease in mitochondrial respiration and ATP production.
Conclusions: These data suggest that lactone- and acid-forms of simvastatin exhibit differential effects on non-oxidative glucose metabolism as lactone-form increases and acid-form impairs glucose storage into glycogen, suggesting impaired insulin sensitivity in response to acid-form simvastatin. Both forms profoundly impair oxidative glucose metabolism and energy production in human skeletal muscle cells. These effects may contribute to muscular side effects and risk for T2D observed with simvastatin use.
Keywords: ATP production; HMG-CoA reductase inhibitor; glucose uptake; glycogen synthesis; glycolysis; insulin resistance; mitochondrial respiration; simvastatin; skeletal muscle.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7780958/bin/EC-20-0444fig6.gif)
Similar articles
-
Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.Diabetologia. 2024 May 30. doi: 10.1007/s00125-024-06185-6. Online ahead of print. Diabetologia. 2024. PMID: 38814443
-
Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression.Biomedicines. 2020 Sep 15;8(9):351. doi: 10.3390/biomedicines8090351. Biomedicines. 2020. PMID: 32942550 Free PMC article.
-
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation.Biochem Biophys Res Commun. 2016 Nov 11;480(2):194-200. doi: 10.1016/j.bbrc.2016.10.026. Epub 2016 Oct 12. Biochem Biophys Res Commun. 2016. PMID: 27743890
-
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.Dan Med J. 2014 Jul;61(7):B4890. Dan Med J. 2014. PMID: 25123125 Review.
-
Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism.Dan Med Bull. 1999 Feb;46(1):13-34. Dan Med Bull. 1999. PMID: 10081651 Review.
Cited by
-
Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.Diabetologia. 2024 May 30. doi: 10.1007/s00125-024-06185-6. Online ahead of print. Diabetologia. 2024. PMID: 38814443
-
Statins affect human iPSC-derived cardiomyocytes by interfering with mitochondrial function and intracellular acidification.Basic Res Cardiol. 2024 Apr;119(2):309-327. doi: 10.1007/s00395-023-01025-x. Epub 2024 Feb 2. Basic Res Cardiol. 2024. PMID: 38305903
-
Induced pluripotent stem cell-derived cells model brain microvascular endothelial cell glucose metabolism.Fluids Barriers CNS. 2022 Dec 9;19(1):98. doi: 10.1186/s12987-022-00395-z. Fluids Barriers CNS. 2022. PMID: 36494870 Free PMC article.
-
Finnish-specific AKT2 gene variant leads to impaired insulin signalling in myotubes.J Mol Endocrinol. 2023 Jan 4;70(2):e210285. doi: 10.1530/JME-21-0285. Print 2023 Feb 1. J Mol Endocrinol. 2023. PMID: 36409629 Free PMC article.
-
Role of Lactone and Acid Forms in the Pleiotropic Effects of Statins.Pharmaceutics. 2022 Sep 8;14(9):1899. doi: 10.3390/pharmaceutics14091899. Pharmaceutics. 2022. PMID: 36145647 Free PMC article.
References
-
- US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FAR, Gillman MW, Kemper AR, Krist AH.et al Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016. 316 1997–2007. (10.1001/jama.2016.15450) - DOI - PubMed
LinkOut - more resources
Full Text Sources